OncoFirm™ Cancer Rapid Tests
Early Cancer Antibody Detection Types
OncoFirm™ Diagnostics is developing a new generation of rapid cancer screening tests designed to detect cancer-associated biomarkers quickly, simply, and at the point of care.
Our rapid test platform focuses on Early Cancer Antibody Detection, using advanced lateral flow technology to help identify biomarker signals associated with specific cancer types and multi-cancer risk profiles.
Rapid Cancer Screening Made More Accessible
Early detection can make a meaningful difference in cancer care. OncoFirm™ rapid tests are being designed to support faster screening workflows for healthcare professionals, clinics, laboratories, and community health programs.
Our tests are intended to provide:
Fast results
Designed for rapid screening workflows.
Simple sample handling
Developed for use with human serum, plasma, or whole blood formats.
Point-of-care convenience
Built for clinical and decentralized healthcare settings.
Digital-ready performance
Compatible with the OncoFirm™ Electronic Reader for enhanced interpretation and reporting.
Early Cancer Antibody Detection Test Types
OncoScreen™ CEA
A rapid test designed to detect Carcinoembryonic Antigen (CEA), a biomarker commonly associated with colorectal and other cancer-related screening applications.
OncoScreen™ PSA
A rapid test designed to detect Prostate-Specific Antigen (PSA) for prostate cancer screening support.
OncoScreen™ AFP
A rapid test designed to detect Alpha-Fetoprotein (AFP), commonly associated with liver cancer screening applications.
OncoScreen™ B
A rapid antibody-based test concept focused on breast and ovarian cancer-associated biomarker detection.
OncoScreen™ L
A rapid antibody-based test concept focused on lung cancer-associated biomarker detection.
OncoScreen™ R
A rapid antibody-based test concept focused on renal cancer-associated biomarker detection.
OncoMultiDx™
A multiplex rapid test platform designed for the simultaneous detection of multiple cancer biomarkers from a single test format.
Powered by Proprietary Lateral Flow Technology
OncoFirm™ rapid tests are being developed using proprietary lateral flow and fluorescent detection methods intended to improve sensitivity, readability, and accessibility in cancer biomarker screening.
When paired with the OncoFirm™ Electronic Reader, test results may be digitally interpreted, stored, and reported to support more consistent clinical workflows.
Designed for Healthcare Professionals
OncoFirm™ rapid cancer screening tests are being developed for professional use in:
- Hospitals
- Physician offices
- Diagnostic laboratories
- Cancer screening programs
- Community health clinics
- Research and clinical validation settings
Our Goal
OncoFirm™ Diagnostics is committed to making early cancer screening faster, more accessible, and easier to deploy across healthcare settings.
By combining rapid antibody-based detection, biomarker science, lateral flow engineering, and digital reader technology, OncoFirm™ is building a platform intended to support earlier detection and better outcomes.
Contact OncoFirm™ Diagnostics
To learn more about OncoFirm™ rapid tests, clinical collaborations, research opportunities, distribution partnerships, or investor inquiries, please contact:
OncoFirm™ Diagnostics Corp.
Email: [email protected]
Website: https://oncofirmdiagnostics.com